GeneDx Holdings Corp (WGS) Stock AnalysisWGSGeneDx Holdings Corp

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

Currently, GeneDx Holdings Corp (WGS) is not a strong buy due to its recent price decline and negative financial indicators. The current price is $56.15, which is down 57.56% year-to-date. The RSI is at 22.92, indicating that the stock is oversold. Although the company reported a record Q2 revenue of $114.4 million, it also posted a net loss of $17.74 million in Q2 2026, raising concerns about profitability. The forward P/E ratio is extremely high at 72.46, suggesting that the stock may be overvalued at this price. The main risk is the significant decline in stock price, with a 5-day change of -11.73%.